Celsion Corporation (CLSN)

[seek the light]

OPPENHEIMER KEEPS A BUY RATING ON CELSION CORP
March 6, 2018 Catie Powers Healthcare Leave a comment

Oppenheimer analyst Hartaj Singh maintained a Buy rating on Celsion Corp (NASDAQ: CLSN) yesterday and set a price target of $9.

Singh noted:

“We recently hosted a presentation by Key Opinion Leader (KOL) Dr. Premal Thaker, who provided an overview of ovarian cancer, the current standard-of-care (SOC) and the potential of existing/novel therapies. The KOL pointed to Celsion’s GEN-1 as having potential in a difficult to treat disease. Ovarian cancer has been one of the more difficult tumor types to treat (see exhibits below), with surgery as the main SOC but chemotherapy also utilized extensively. New approaches like immunotherapy and targeted therapies have demonstrated some utility, but only in specific populations. Combination approaches are being tested in this setting. GEN-1 has demonstrated an ORR of 86% in an early stage trial presented at AACR 2017 and is now in Phase 1/2. We stay bullish.”

According to TipRanks.com, Singh is a 5-star analyst with an average return of 29.7% and a 60.0% success rate. Singh covers the Healthcare sector, focusing on stocks such as Strongbridge Biopharma Plc, Syndax Pharmaceuticals Inc, and Catabasis Pharmaceuticals.

Celsion Corp has an analyst consensus of Hold.